short-term Deanxit in combination with Sertraline treats somatic disease accompanied with depressive disorder

A new strategy: short-term Deanxit in combination with Sertraline treats somatic disease accompanied with depressive disorder

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001732

Enrollment

Unknown

Registered

2011-11-25

Start date

2010-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

somatic disease accompanied with depressive disorder

Interventions

treatment group:Sertraline and Deanxit

control group:Sertraline

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients either male or female outpatients or inpatients aged 20-75 years and met CCMD-III diagnostic criteria of depressive disorder with somatic disease could enter the study.

Exclusion criteria

Exclusion criteria: The exclusion criteria included serious damage in heart, liver, and kidney; pregnancy or breastfeeding women; epilepsy; antidepressant treatment at last month.

Design outcomes

Primary

Measure	Time frame
Hamilton Depression Scale, HAMD;Hamilton Anxiety Scale, HAMD;	—

Countries

China

Contacts

Public ContactZhonglin Liu

zhonglinliu@126.com+86 13719438236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026